Complementary Alternative Medicine for Reconstitution of CD4 count and Quality of Life in HIV-Infected Patients with Advanced Disease

HIV-Infected Patients with Advanced Disease in treatment with HAART use Complementary Alternative Medicine for Reconstitution of CD4 count and for Improving their Health Related Quality of Life over Time

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN03831044

Enrollment

Registered

2010-07-08

Start date

2007-06-05

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV-Infected Patients with Advanced Disease under HAART Infections and Infestations Human immunodeficiency virus [HIV] disease

Interventions

The same physician will be in charge of the CAM treatment throughout, indicating treatment, controlling its effects, adjusting therapy and also indicating additional controls with the physician in cha

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Any adult patient infected with HIV who has a naïve CD4 count 48 weeks of HAART, keep CD4 < 250 cell/mL 2. Adherent to HAART and to the controls with the physician in charge of treatment of the HIV-condition 3. Patients who modify their HAART regimens are not excluded if plasma HIV-1 RNA levels, remain < 80 copies/mL

Exclusion criteria

Exclusion criteria: Patients who use hydroxyurea, IL-2, IFN-a, or the combination of tenofovir and didanosine, which are known to affect CD4 count increases

Design outcomes

Primary

Measure	Time frame
1. CD4 cell count and viral load, measured every 3 months Viral load was considered undetectable with < 80 UI/mL copies using Nuclisens Easy Q HIV-1, Bio Mérieux test 2. Quality of Life, measured by Medical Outcomes Study Short Form 30 (MOS-SF-30) validated for people infected by HIV, answered privately by the patient every 3 months	—

Secondary

Measure	Time frame
1. Incidence of hospitalisation 2. Opportunistic infection 3. Death 4. Side effects of CAM 5. Interaction of HAART and CAM	—

Countries

Chile

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026